68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies

Malik, Dharmender; Kumar, Rajender; Mittal, Bhagwant Rai; Singh, Harmandeep; Bhattacharya, Anish; Singh, Shrawan Kumar

doi:10.1097/rlu.0000000000002103

Cited by 43 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, PSMA PET is not as specific for prostate cancer as previously thought. An increasing number of nonprostatic disorders have shown PSMA expression (79,80), including inflammatory/infectious diseases, vascular conditions, benign neoplasms, and other malignancies. Awareness of these findings may prevent misinterpretation.…”

Section: Distant Recurrencementioning

confidence: 99%

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

et al. 2019

View full text Add to dashboard Cite

The introduction of prostate-specific membrane antigen (PSMA) in clinical practice has revolutionized evaluation of biochemical recurrence of prostate cancer after curative-intent treatment. The high expression of this glycoprotein in prostate cancer cells makes PSMA imaging superior to the current conventional staging methods, namely bone scanning and CT. The high capability of PSMA imaging for identifying very small previously undetected lesions has been widely demonstrated in the literature, leading to a rethinking of patient management by oncologists, urologists, and radiation oncologists. The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging. Furthermore, it is important for the reading physician to recognize and understand the typical disease spread and the most prevalent atypical prostate cancer relapses, not only to heighten the relevancy of reports but also to improve imaging consultancy in multispecialty oncologic practice. ©

show abstract

Section: Distant Recurrencementioning

confidence: 99%

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

et al. 2019

View full text Add to dashboard Cite

show abstract

“…7 First described in studies of monoclonal antibodies to a novel antigenic marker in PC in the late 1980s, [8][9][10] it has rapidly become clear that despite its name, the expression of this transmembrane protein is not restricted to PC. It also can be found in normal prostatic tissue and the vascular endothelium in a wide variety of solid tumors, 11,12 but not in blood vessels of normal tissues. Physiologic PSMA expression is reported in the lacrimal and salivary glands, the liver, the spleen, the kidneys, and the intestines.…”

Section: Prostate-specific Membrane Antigenmentioning

confidence: 99%

Prostate Cancer Theranostics

et al. 2021

View full text Add to dashboard Cite

“…68 Ga-PSMA, which is a tumor-specific antigen that was first used in prostate cancer staging, has been repeatedly utilized and is rapidly becoming a complementary tracer for breast cancers with low FDG avidities. High PSMA uptake has been exhibited in invasive ductal carcinoma, triple-negative breast cancer, and rare pathological subtypes such as Signet-ring cell breast adenocarcinoma ( 110 – 112 , 127 ). Like 18 F-FDG, tracers based on cellular metabolism are continuously being studied.…”

Section: Recent Advances In Pet-based Strategiesmentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies

Cited by 43 publications

References 9 publications

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Prostate Cancer Theranostics

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Contact Info

Product

Resources

About